CapsoVision (NASDAQ:CV) Major Shareholder Acquires $9,999,998.61 in Stock

CapsoVision, Inc. (NASDAQ:CV) major shareholder Eliyahou Et Al Harari acquired 1,757,469 shares of CapsoVision stock in a transaction dated Friday, September 18th. The shares were purchased at an average price of $5.69 per share, for a total transaction of $9,999,998.61. Following the completion of the transaction, the insider directly owned 1,396,494 shares in the company, valued at approximately $7,946,050.86. The trade was a -486.87% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Eliyahou Et Al Harari also recently made the following trade(s):

• On Friday, July 17th, Eliyahou Et Al Harari bought 61,068 shares of CapsoVision stock. The stock was purchased at an average price of $6.73 per share, with a total value of $410,987.64.
• On Wednesday, July 8th, Eliyahou Et Al Harari bought 81,300 shares of CapsoVision stock. The stock was purchased at an average cost of $6.09 per share, with a total value of $495,117.00.
• On Friday, June 26th, Eliyahou Et Al Harari purchased 13,850 shares of CapsoVision stock. The shares were acquired at an average cost of $7.35 per share, for a total transaction of $101,797.50.

CapsoVision Stock Up 7.8%

CapsoVision stock opened at $6.65 on Friday. CapsoVision, Inc. has a twelve month low of $4.34 and a twelve month high of $15.37. The firm has a fifty day simple moving average of $6.40 and a two-hundred day simple moving average of $6.56. The company has a market capitalization of $332.83 million, a PE ratio of -14.15 and a beta of -2.47.

CapsoVision (NASDAQ:CV) last issued its earnings results on Thursday, August 13th. The company reported ($0.15) earnings per share for the quarter. CapsoVision had a negative net margin of 214.74% and a negative return on equity of 177.85%. The company had revenue of $3.64 million for the quarter. As a group, equities analysts expect that CapsoVision, Inc. will post -0.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on CV. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CapsoVision in a research report on Monday, June 29th. Roth Capital initiated coverage on CapsoVision in a research note on Friday, August 28th. They set a “buy” rating and a $9.00 target price on the stock. Zacks Research upgraded CapsoVision to a “hold” rating in a report on Monday, August 31st. Finally, Benchmark reaffirmed a “speculative buy” rating on shares of CapsoVision in a research note on Friday, August 14th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $9.50.

Institutional Trading of CapsoVision

Several institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. bought a new position in shares of CapsoVision in the 2nd quarter worth approximately $14,372,000. Bank of New York Mellon Corp bought a new position in CapsoVision in the second quarter worth $569,000. Deutsche Bank AG purchased a new position in CapsoVision during the second quarter valued at $263,000. Bank of America Corp DE bought a new stake in shares of CapsoVision during the 2nd quarter valued at $193,000. Finally, Connective Capital Management LLC bought a new stake in shares of CapsoVision during the 2nd quarter valued at $76,000.

About CapsoVision

CapsoVision, Inc is a medical technology company focused on developing and commercializing capsule endoscopy systems for gastrointestinal (GI) diagnostics. Its products are designed to help physicians examine the digestive tract, particularly the small intestine, using an ingestible capsule rather than a conventional endoscopic procedure.

The company’s principal product is CapsoCam Plus, an ingestible capsule endoscope that captures panoramic images as it travels through the gastrointestinal tract.